Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
出版年份 2020 全文链接
标题
Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
作者
关键词
-
出版物
Scientific Reports
Volume 10, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-06-23
DOI
10.1038/s41598-020-67199-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors
- (2019) Anna Yordanova et al. CLINICAL NUCLEAR MEDICINE
- The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours
- (2019) Aldo Scarpa ANNALES D ENDOCRINOLOGIE
- Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours
- (2019) Samuel Adant et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines
- (2018) Tobias Hofving et al. ENDOCRINE-RELATED CANCER
- Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
- (2018) Nupur K. Purohit et al. Oncotarget
- A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-Resistant Tumors
- (2018) Chester E. Chamberlain et al. MOLECULAR CANCER THERAPEUTICS
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line
- (2017) Jacob J. Henderson et al. PEDIATRIC BLOOD & CANCER
- Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
- (2017) Paul Lesueur et al. Oncotarget
- The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors
- (2017) Lisa Bodei et al. Journal of Thoracic Disease
- Upregulation of Key Molecules for Targeted Imaging and Therapy
- (2016) V. F. Taelman et al. JOURNAL OF NUCLEAR MEDICINE
- Origin of the U87MG glioma cell line: Good news and bad news
- (2016) Marie Allen et al. Science Translational Medicine
- Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
- (2016) Julie Nonnekens et al. Theranostics
- The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis
- (2015) Seong-Jang Kim et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)
- (2014) G. Kong et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours
- (2014) Raghava Kashyap et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion
- (2013) Raghava Kashyap et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?
- (2013) Michael S. Hofman et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Improving Diagnosis of Tumor-Induced Osteomalacia With Gallium-68 DOTATATE PET/CT
- (2013) Roderick J. Clifton-Bligh et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Treatment of Triple-Negative Breast Cancer Using Anti-EGFR-Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor
- (2013) F. Al-Ejeh et al. JOURNAL OF NUCLEAR MEDICINE
- PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy
- (2013) Jeremy P.H. Chow et al. MOLECULAR CANCER THERAPEUTICS
- The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
- (2012) Mike De Vos et al. BIOCHEMICAL PHARMACOLOGY
- Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors
- (2012) Phillip G. Claringbold et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Hypersensibilité à la radiothérapie chez un patient atteint de la sclérose tubéreuse de Bourneville : réflexions biologiques à partir d’un cas clinique
- (2012) B. Duchemain et al. Cancer Radiotherapie
- Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers
- (2012) Linda Villard et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Toxicity of 131I-Metaiodobenzylguanidine/Topotecan Combination Therapy to Cells and Xenografts That Express the Noradrenaline Transporter
- (2012) A. G. McCluskey et al. JOURNAL OF NUCLEAR MEDICINE
- Radionuclide Therapy via SSTR: Future Aspects from Experimental Animal Studies
- (2012) Eva Forssell-Aronsson et al. NEUROENDOCRINOLOGY
- Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft
- (2011) J. M. Senra et al. MOLECULAR CANCER THERAPEUTICS
- Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy
- (2011) R.J. Hicks CANCER IMAGING
- Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set
- (2010) David S. Klimstra et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
- (2010) Daniel Hubble et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
- (2010) Phillip G. Claringbold et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
- (2010) Dik J. Kwekkeboom et al. SEMINARS IN NUCLEAR MEDICINE
- High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience
- (2009) Grace Kong et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
- (2009) J. P. Palma et al. CLINICAL CANCER RESEARCH
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- (2009) Dik J Kwekkeboom et al. ENDOCRINE-RELATED CANCER
- Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
- (2008) Martijn van Essen et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Gastroenteropancreatic neuroendocrine tumours
- (2008) Irvin M Modlin et al. LANCET ONCOLOGY
- Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks
- (2008) X. Liu et al. MOLECULAR CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started